These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 38965558)
1. GNA13 suppresses proliferation of ER+ breast cancer cells via ERα dependent upregulation of the MYC oncogene. Subramanyan LV; Rasheed SAK; Wang L; Ghosh S; Ong MSN; Lakshmanan M; Wang M; Casey PJ Breast Cancer Res; 2024 Jul; 26(1):113. PubMed ID: 38965558 [TBL] [Abstract][Full Text] [Related]
2. The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins. Teo CR; Casey PJ; Rasheed SA Cell Signal; 2016 Oct; 28(10):1479-88. PubMed ID: 27424208 [TBL] [Abstract][Full Text] [Related]
3. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells. O'Hayre M; Inoue A; Kufareva I; Wang Z; Mikelis CM; Drummond RA; Avino S; Finkel K; Kalim KW; DiPasquale G; Guo F; Aoki J; Zheng Y; Lionakis MS; Molinolo AA; Gutkind JS Oncogene; 2016 Jul; 35(29):3771-80. PubMed ID: 26616858 [TBL] [Abstract][Full Text] [Related]
4. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351 [TBL] [Abstract][Full Text] [Related]
5. The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors. Rasheed SAK; Subramanyan LV; Lim WK; Udayappan UK; Wang M; Casey PJ Oncogene; 2022 Jan; 41(2):147-158. PubMed ID: 34689178 [TBL] [Abstract][Full Text] [Related]
7. GNA13 as a prognostic factor and mediator of gastric cancer progression. Zhang JX; Yun M; Xu Y; Chen JW; Weng HW; Zheng ZS; Chen C; Xie D; Ye S Oncotarget; 2016 Jan; 7(4):4414-27. PubMed ID: 26735177 [TBL] [Abstract][Full Text] [Related]
8. Naturally occurring hotspot cancer mutations in Gα Maziarz M; Federico A; Zhao J; Dujmusic L; Zhao Z; Monti S; Varelas X; Garcia-Marcos M J Biol Chem; 2020 Dec; 295(49):16897-16904. PubMed ID: 33109615 [TBL] [Abstract][Full Text] [Related]
9. Gα-13 induces C Lim WK; Chai X; Ghosh S; Ray D; Wang M; Rasheed SAK; Casey PJ J Biol Chem; 2019 Nov; 294(48):18192-18206. PubMed ID: 31636124 [TBL] [Abstract][Full Text] [Related]
10. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer. Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells. Rasheed SA; Teo CR; Beillard EJ; Voorhoeve PM; Zhou W; Ghosh S; Casey PJ Mol Cancer; 2015 Mar; 14():67. PubMed ID: 25889182 [TBL] [Abstract][Full Text] [Related]
12. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. Li M; Li A; Zhou S; Lv H; Yang W J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840 [TBL] [Abstract][Full Text] [Related]
13. The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells. Gardner JA; Ha JH; Jayaraman M; Dhanasekaran DN Pancreas; 2013 Jul; 42(5):819-28. PubMed ID: 23508014 [TBL] [Abstract][Full Text] [Related]
14. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway. Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829 [TBL] [Abstract][Full Text] [Related]
15. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042 [TBL] [Abstract][Full Text] [Related]
16. Divergent C-terminal motifs in Gα12 and Gα13 provide distinct mechanisms of effector binding and SRF activation. Stecky RC; Quick CR; Fleming TL; Mull ML; Vinson VK; Whitley MS; Dover EN; Meigs TE Cell Signal; 2020 Aug; 72():109653. PubMed ID: 32330601 [TBL] [Abstract][Full Text] [Related]
17. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer. Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511 [TBL] [Abstract][Full Text] [Related]
18. Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling. Lü J; Zhao Q; Guo Y; Li D; Xie H; Liu C; Hu X; Liu S; Hou Z; Wei X; Zheng D; Pestell RG; Yu Z J Exp Clin Cancer Res; 2023 Apr; 42(1):93. PubMed ID: 37081505 [TBL] [Abstract][Full Text] [Related]